| Theme | The New Guideline for Liver Cancer Treatment | |
|---|---|---|
| Title | Cancer Medical Treatment | |
| Publish Date | 2018/06 | |
| Author | Tatsuya Yamashita | Department of Gastroenterology, Kanazawa University Hospital |
| Author | Takeshi Terashima | Department of Gastroenterology, Kanazawa University Hospital |
| Author | Kuniaki Arai | Department of Gastroenterology, Kanazawa University Hospital |
| Author | Shuichi Kaneko | Department of Gastroenterology, Kanazawa University Hospital |
| [ Summary ] | Based on revised Japanese clinical practice guidelines for hepatocellular carcinoma (HCC) that were launched in October 2017, cancer medical treatments are recommended for patients with advanced HCC, extrahepatic metastases, vascular invasion, or intrahepatic multiple lesions refractory to transarterial chemoembolization. As molecular target drugs, sorafenib or lenvatinib are strongly recommended as first-line therapy. However, lenvatinib has not been evaluated in practice because of its recent approval. Regorafenib is also strongly recommended in patients with limited indications for second-line therapy after sorafenib. Hepatic arterial infusion chemotherapy is weakly recommended for patients with intrahepatic advanced lesions, such as major vascular invasion or intrahepatic multiple lesions with high tumor burden. We must improve prognosis in patients with advanced HCC through proper administration of these medical cancer treatments. | |